Diabetes and Colorectal Cancer Risk and Survival According to Tumor Immunity Status
T2D disproportionately affects CRC risk and survival in tumors with low immune infiltration, suggesting a continuum of T2D's impact from tumorigenesis to prognosis, through systemic and tumor-specific immune modulation. These findings highlight the need for precision prevention strategies integrating metabolic and immune-based interventions to mitigate CRC burden in patients with T2D.
Authors
- Michael Hoffmeister (ORCID: https://orcid.org/0000-0002-8307-3197)
- Durgesh Wankhede (ORCID: https://orcid.org/0000-0003-2583-9032)
- Niels Halama (ORCID: https://orcid.org/0000-0003-0344-6027)
- Hermann Brenner (ORCID: https://orcid.org/0000-0002-6129-1572)
- Matthias Kloor (ORCID: https://orcid.org/0000-0002-4125-992X)
Institutions
- German Cancer Research Center (DE)
- Johannes Gutenberg University Mainz (DE)
- Heidelberg University (DE)
- University Hospital Heidelberg (DE)
- National Center for Tumor Diseases (DE)
- Helmholtz Institute Mainz (DE)
Publication Details
- Journal
- Journal of Clinical Oncology
- Published
- 2025-07-14
- DOI
- https://doi.org/10.1200/jco-25-00148
- Citations
- 2
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 2.09